RxDoctor Payments Data

Colleen Vanderkolk, DO

Neurology · Nashville, TNNPI 1811935711

Payments from drug & device makers

$31,929in general payments, 2019–2025

Across 129 payments — averaging $247.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$24K
  • SK Life Science, Inc.$7K
  • AbbVie$477
  • Pfizer$168
  • UCB, Inc.$96
  • Amgen$59
  • plus $278 from 11 others

What the payments were for

  • Speaking & faculty fees$27,87587%
  • Travel & lodging$1,9716%
  • Food & beverage$2,0536%
  • Education$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,929 in reported general payments places this provider in the 75th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$117,533
Medicare patients
350
Services billed
9,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)24$103,207
AptiomEslicarbazepine Acetate25$101,320
XcopriCenobamate37$42,920
Aimovig AutoinjectorErenumab-Aooe32$39,963
BriviactBrivaracetam25$36,961
Nurtec OdtRimegepant Sulfate30$34,877
Emgality PenGalcanezumab-Gnlm36$31,067
VimpatLacosamide24$25,797
BotoxOnabotulinumtoxina19$24,935
Ajovy AutoinjectorFremanezumab-Vfrm25$22,117
Rufinamide12$15,004
KeppraLevetiracetam12$14,884
Lacosamide94$10,864
LamictalLamotrigine12$10,596
NayzilamMidazolam11$8,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$30$101,32025 claims
UCB, Inc.Briviact, Vimpat, Nayzilam$96$71,32860 claims
PfizerNurtec Odt, Lyrica, Dilantin$168$46,06359 claims
SK Life Science, Inc.Xcopri$6,829$42,92037 claims
AbbVieBotox$477$24,93519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 361 neurology providers in Tennessee.

Other neurology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →